HAVANA, Cuba, Oct 12 (acn) More than 100 experts of Cuba and Brazil will exchange experiences on the recombinant human erythropoietin, a biotechnological medicine of high efficiency in the treatment of anemia associated to different types of diseases.
Scheduled for October 13 and 14, the Cuba-Brazil Workshop "Generalization of the use of erythropoietin in the National Health System," under way at Havana's Convention Center, is aimed at promoting scientific exchanges on the clinical results and benefits of the product developed at the capital's Molecular Immunology Center (CIM).
Introduced in medical practice 15 years ago, this biotechnological drug has benefited over 250,000 patients of Cuba and other countries where it has been exported, mainly to Latin America, Central America and the Caribbean, announced sources of the organizing committee.
The meeting's debates will also focus on the results of clinical trials and safety analyses of the product, one of the leaders of the CIM, which is registered in some 20 nations.
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio